Delayed
TEL AVIV STOCK EXCHANGE
|
5-day change
|
1st Jan Change
|
- ILa
|
-.--%
|
|
-2.55%
|
-3.73%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,031
|
6,104
|
5,204
|
4,590
|
4,361
|
3,716
|
-
|
-
|
Enterprise Value (EV)
1 |
10,046
|
9,028
|
6,859
|
8,096
|
7,683
|
6,925
|
6,728
|
6,529
|
P/E ratio
|
48.3
x
|
-37.6
x
|
-74.8
x
|
-32.8
x
|
-358
x
|
-18.8
x
|
170
x
|
23.9
x
|
Yield
|
1.59%
|
2.01%
|
2.47%
|
3.05%
|
3.39%
|
4.04%
|
4.3%
|
4.63%
|
Capitalization / Revenue
|
1.45
x
|
1.21
x
|
1.26
x
|
1.03
x
|
0.94
x
|
0.8
x
|
0.77
x
|
0.74
x
|
EV / Revenue
|
2.08
x
|
1.78
x
|
1.66
x
|
1.82
x
|
1.65
x
|
1.5
x
|
1.39
x
|
1.3
x
|
EV / EBITDA
|
11.2
x
|
10.2
x
|
11.9
x
|
14
x
|
11.6
x
|
9.67
x
|
8.29
x
|
7.68
x
|
EV / FCF
|
40.2
x
|
19.4
x
|
1,715
x
|
38.4
x
|
25.3
x
|
14.8
x
|
13.2
x
|
12
x
|
FCF Yield
|
2.49%
|
5.16%
|
0.06%
|
2.61%
|
3.95%
|
6.74%
|
7.6%
|
8.36%
|
Price to Book
|
1.21
x
|
1.05
x
|
1.01
x
|
0.95
x
|
0.91
x
|
0.73
x
|
0.7
x
|
0.67
x
|
Nbr of stocks (in thousands)
|
1,36,110
|
1,36,491
|
1,33,774
|
1,34,640
|
1,35,506
|
1,36,320
|
-
|
-
|
Reference price
2 |
51.66
|
44.72
|
38.90
|
34.09
|
32.18
|
27.26
|
27.26
|
27.26
|
Announcement Date
|
27/02/20
|
01/03/21
|
01/03/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4,837
|
5,063
|
4,139
|
4,452
|
4,656
|
4,623
|
4,837
|
5,015
|
EBITDA
1 |
894.4
|
885.6
|
578
|
576.9
|
663.9
|
716.2
|
811.6
|
850.6
|
EBIT
1 |
809.2
|
795.8
|
479
|
492.3
|
574.3
|
611
|
712.9
|
781.2
|
Operating Margin
|
16.73%
|
15.72%
|
11.57%
|
11.06%
|
12.34%
|
13.22%
|
14.74%
|
15.58%
|
Earnings before Tax (EBT)
1 |
171
|
-
|
-
|
-139.1
|
-8.3
|
-138.4
|
139.7
|
266.6
|
Net income
1 |
146.1
|
-162.6
|
-68.9
|
-140.6
|
-12.7
|
-73.65
|
107.1
|
208.4
|
Net margin
|
3.02%
|
-3.21%
|
-1.66%
|
-3.16%
|
-0.27%
|
-1.59%
|
2.21%
|
4.16%
|
EPS
2 |
1.070
|
-1.190
|
-0.5200
|
-1.040
|
-0.0900
|
-1.450
|
0.1600
|
1.140
|
Free Cash Flow
1 |
250.1
|
465.8
|
4
|
210.9
|
303.8
|
467
|
511
|
546
|
FCF margin
|
5.17%
|
9.2%
|
0.1%
|
4.74%
|
6.53%
|
10.1%
|
10.56%
|
10.89%
|
FCF Conversion (EBITDA)
|
27.96%
|
52.6%
|
0.69%
|
36.56%
|
45.76%
|
65.2%
|
62.96%
|
64.19%
|
FCF Conversion (Net income)
|
171.18%
|
-
|
-
|
-
|
-
|
-
|
477.12%
|
262%
|
Dividend per Share
2 |
0.8200
|
0.9000
|
0.9600
|
1.040
|
1.090
|
1.102
|
1.172
|
1.263
|
Announcement Date
|
27/02/20
|
01/03/21
|
01/03/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1,105
|
1,074
|
1,122
|
1,100
|
1,155
|
1,182
|
1,193
|
1,124
|
1,157
|
1,082
|
1,163
|
1,162
|
1,216
|
1,152
|
1,210
|
EBITDA
1 |
153.3
|
107.4
|
136.7
|
153.3
|
178.7
|
142.7
|
161.5
|
173
|
186.6
|
115.7
|
164.5
|
203
|
223.2
|
191.5
|
208.6
|
EBIT
1 |
131.5
|
86.8
|
116.4
|
133
|
156
|
119.6
|
137.3
|
150.3
|
167.1
|
93
|
138.8
|
178.8
|
201.5
|
169.2
|
180.3
|
Operating Margin
|
11.9%
|
8.08%
|
10.38%
|
12.09%
|
13.5%
|
10.12%
|
11.51%
|
13.37%
|
14.44%
|
8.59%
|
11.94%
|
15.4%
|
16.57%
|
14.68%
|
14.9%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-3.5
|
-14.3
|
4.3
|
-
|
-
|
-54.4
|
-98.6
|
-43.45
|
-7.05
|
10.9
|
50.2
|
60.9
|
Net income
1 |
-
|
-
|
-
|
-49.4
|
-23.7
|
-
|
8.4
|
-
|
-32.3
|
2
|
-31.7
|
-4.75
|
-39.15
|
37.8
|
46.3
|
Net margin
|
-
|
-
|
-
|
-4.49%
|
-2.05%
|
-
|
0.7%
|
-
|
-2.79%
|
0.18%
|
-2.73%
|
-0.41%
|
-3.22%
|
3.28%
|
3.83%
|
EPS
|
-
|
-
|
-
|
-0.3700
|
-0.1700
|
-0.0200
|
0.0600
|
-
|
-0.2400
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.2400
|
0.2600
|
0.2600
|
0.2600
|
0.2600
|
0.2700
|
0.2700
|
0.2700
|
0.2800
|
-
|
0.2800
|
0.2800
|
0.2800
|
-
|
-
|
Announcement Date
|
01/03/22
|
11/05/22
|
09/08/22
|
08/11/22
|
27/02/23
|
09/05/23
|
08/08/23
|
07/11/23
|
27/02/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
3,015
|
2,925
|
1,656
|
3,506
|
3,322
|
3,209
|
3,012
|
2,813
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.371
x
|
3.302
x
|
2.864
x
|
6.077
x
|
5.004
x
|
4.48
x
|
3.711
x
|
3.307
x
|
Free Cash Flow
1 |
250
|
466
|
4
|
211
|
304
|
467
|
511
|
546
|
ROE (net income / shareholders' equity)
|
9.58%
|
9.74%
|
5.14%
|
5.62%
|
7.33%
|
7.15%
|
8.37%
|
8.75%
|
ROA (Net income/ Total Assets)
|
1.31%
|
-1.43%
|
2.53%
|
2.62%
|
3.23%
|
3.28%
|
4.05%
|
4.38%
|
Assets
1 |
11,142
|
11,395
|
-2,720
|
-5,366
|
-393.7
|
-2,246
|
2,646
|
4,761
|
Book Value Per Share
2 |
42.60
|
42.50
|
38.50
|
35.90
|
35.20
|
37.30
|
39.10
|
40.90
|
Cash Flow per Share
|
2.840
|
-
|
-
|
-
|
3.000
|
-
|
-
|
-
|
Capex
1 |
138
|
170
|
152
|
96.4
|
102
|
113
|
118
|
123
|
Capex / Sales
|
2.85%
|
3.37%
|
3.68%
|
2.17%
|
2.18%
|
2.44%
|
2.43%
|
2.44%
|
Announcement Date
|
27/02/20
|
01/03/21
|
01/03/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
27.26
USD Average target price
39.5
USD Spread / Average Target +44.90% Consensus |
1st Jan change
|
Capi.
|
---|
| +48.39% | 779B | | -6.13% | 354B | | +20.61% | 333B | | +10.00% | 301B | | +17.55% | 249B | | -1.84% | 216B | | +11.15% | 214B | | +5.80% | 163B | | -2.50% | 159B |
Other Pharmaceuticals
|